Literature DB >> 12832665

Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol.

L G Heaney1, E Conway, C Kelly, B T Johnston, C English, M Stevenson, J Gamble.   

Abstract

BACKGROUND: It has been suggested that asthmatic subjects with persisting symptoms despite adequate maintenance therapy should be systematically evaluated to identify factors contributing to poor control. The aims of this study were to examine the prevalence of these factors in a cohort of sequentially referred poorly controlled asthmatics, and to determine if any factor or combination of factors predicted true therapy resistant asthma (TRA).
METHODS: Patients were evaluated using a systematic evaluation protocol including induced sputum analysis, psychiatric assessment, ear, nose and throat examination, pulmonary function testing, high resolution CT scan of the thorax, and 24 hour dual probe ambulatory oesophageal pH monitoring; any identified provoking factor was treated. Asthma was managed according to BTS guidelines.
RESULTS: Of 73 subjects who completed the assessment, 39 responded to intervention and 34 had TRA. Subjects with TRA had a greater period of instability, a higher dose of inhaled steroids at referral, more rescue steroid use, and a lower best percentage forced expiratory volume in 1 second (FEV(1)%). Oesophageal reflux, upper airway disease, and psychiatric morbidity were common (57%, 95%, 49%, respectively) but were not more prevalent in either group. Using multivariate logistic regression analysis, inhaled steroid dose >2000 micro g BDP, previous assessment by a respiratory specialist, and initial FEV(1)% of <70% at referral predicted a final diagnosis of TRA.
CONCLUSIONS: In poorly controlled asthmatics there is a high prevalence of co-morbidity, identified by detailed systematic assessment, but no difference in prevalence between those who respond to intervention and those with TRA. Targeted treatment of identified co-morbidities has minimal impact on asthma related quality of life in those with therapy resistant disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12832665      PMCID: PMC1746731          DOI: 10.1136/thorax.58.7.561

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  11 in total

Review 1.  Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society.

Authors:  K F Chung; P Godard; E Adelroth; J Ayres; N Barnes; P Barnes; E Bel; P Burney; P Chanez; G Connett; C Corrigan; J de Blic; L Fabbri; S T Holgate; P Ind; G Joos; H Kerstjens; P Leuenberger; C G Lofdahl; S McKenzie; H Magnussen; D Postma; M Saetta; S Salmeron; P Sterk
Journal:  Eur Respir J       Date:  1999-05       Impact factor: 16.671

2.  Factors associated with persistent airflow limitation in severe asthma.

Authors:  A ten Brinke; A H Zwinderman; P J Sterk; K F Rabe; E H Bel
Journal:  Am J Respir Crit Care Med       Date:  2001-09-01       Impact factor: 21.405

Review 3.  Difficult asthma.

Authors:  P J Barnes; A J Woolcock
Journal:  Eur Respir J       Date:  1998-11       Impact factor: 16.671

Review 4.  Efficacy and safety of inhaled corticosteroids. New developments.

Authors:  P J Barnes; S Pedersen; W W Busse
Journal:  Am J Respir Crit Care Med       Date:  1998-03       Impact factor: 21.405

5.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

Authors:  E F Juniper; G H Guyatt; A Willan; L E Griffith
Journal:  J Clin Epidemiol       Date:  1994-01       Impact factor: 6.437

Review 6.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.

Authors:  P H Quanjer; G J Tammeling; J E Cotes; O F Pedersen; R Peslin; J C Yernault
Journal:  Eur Respir J Suppl       Date:  1993-03

7.  Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma.

Authors:  Stuart A Little; Kirsten J MacLeod; George W Chalmers; Janet G Love; Charles McSharry; Neil C Thomson
Journal:  Am J Med       Date:  2002-04-15       Impact factor: 4.965

8.  Difficult-to-control asthma. Contributing factors and outcome of a systematic management protocol.

Authors:  R S Irwin; F J Curley; C L French
Journal:  Chest       Date:  1993-06       Impact factor: 9.410

9.  Measuring quality of life in asthma.

Authors:  E F Juniper; G H Guyatt; P J Ferrie; L E Griffith
Journal:  Am Rev Respir Dis       Date:  1993-04

10.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

View more
  30 in total

1.  A cross-sectional study evaluating the relationship between cortisol suppression and asthma control in patients with difficult asthma.

Authors:  S Aburuz; L G Heaney; J Millership; J Gamble; J McElnay
Journal:  Br J Clin Pharmacol       Date:  2007-01       Impact factor: 4.335

2.  Preview of highlighted presentations from the European Respiratory Society' clinical assembly.

Authors:  Nicolas Kahn; Lowie E G W Vanfleteren; Georgios Kaltsakas; Vasileios Andrianopoulos; Daniela Gompelmann; Corina de Jong; Felix J F Herth
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 3.  Refractory asthma - An old disorder: Novel approaches for effective control.

Authors:  B N B M Prasad
Journal:  Med J Armed Forces India       Date:  2016-06-24

4.  Treatment options in type-2 low asthma.

Authors:  Timothy S C Hinks; Stewart J Levine; Guy G Brusselle
Journal:  Eur Respir J       Date:  2021-01-21       Impact factor: 16.671

5.  Omalizumab: the evidence for its place in the treatment of allergic asthma.

Authors:  Diarmuid M McNicholl; Liam G Heaney
Journal:  Core Evid       Date:  2008-06

Review 6.  Severe asthma: what makes it so hard to manage?

Authors:  Luke Carlstrom; Mario Castro
Journal:  Curr Allergy Asthma Rep       Date:  2009-09       Impact factor: 4.806

Review 7.  The association between gastro-oesophageal reflux disease and asthma: a systematic review.

Authors:  B D Havemann; C A Henderson; H B El-Serag
Journal:  Gut       Date:  2007-08-06       Impact factor: 23.059

8.  PILL Series. The 'problematic' asthma patient.

Authors:  Swee Leng Kui; Choon How How; Jansen Koh
Journal:  Singapore Med J       Date:  2015-07       Impact factor: 1.858

Review 9.  The potential of biologics for the treatment of asthma.

Authors:  Girolamo Pelaia; Alessandro Vatrella; Rosario Maselli
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

10.  TH17 cells and corticosteroid insensitivity in severe asthma.

Authors:  Yan Xie; Peter W Abel; Thomas B Casale; Yaping Tu
Journal:  J Allergy Clin Immunol       Date:  2021-12-23       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.